BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

BriaCell to Present Clinical Findings at the 2019 San Antonio Breast Cancer Symposium® December 12th and 13th

Safety and early efficacy data to be presented from clinical trial of Bria-IMT™ in combination with immune checkpoint inhibitors in advanced breast cancer:
Bria-IMT™ in combination with pembrolizumab (KEYTRUDA®; by Merck & Co., Inc.);Bria-IMT™ in combination with INCMGA00012 (by Incyte Corporation).BERKELEY, Calif. and VANCOUVER, British Columbia, Nov. 12, 2019 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer, is pleased to announce its lead product candidate,  Bria-IMT™,  will be featured in two poster sessions during the 2019 San Antonio Breast Cancer Symposium® (SABCS) taking place December 10-14 in San Antonio, Texas. 
The December 12th poster will summarize the data of the Bria-IMT™ monotherapy study and the ongoing Phase I/IIa clinical study of Bria-IMT™ in combination with immune checkpoint inhibitors including pembrolizumab (KEYTRUDA®; manufactured by Merck & Co., Inc.), and more recently, Incyte’s INCMGA00012, in advanced breast cancer. The December 13th poster presentation will address early predictors of effectiveness of the Bria-IMT™ regimen in advanced breast cancer.“The early clinical findings for Bria-IMT™ in combination with checkpoint inhibitors in advanced breast cancer patients are very encouraging,” said Dr. Bill Williams, President & CEO of BriaCell. “We look forward to continuing our clinical trial with the goal of developing novel treatments for advanced breast cancer patients with no effective treatment options.”Details on the poster presentations are as follows:Program Number: P3-09-08
Presentation Title:  Efficacy and safety of a modified whole tumor cell targeted immunotherapy in patients with advanced breast cancer alone and in combination with immune checkpoint inhibitors 
Session Title:  Poster Session 3
Session Date:  Thursday, December 12, 2019
Session Time: 5:00 – 7:00p.m. CT (6:00 – 8:00 p.m. ET)
Location: Hall 1, Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 USA

CBJ Newsmakers

Recommended
Heighten the holiday spirit with Canndora’s sexy new HighOnLove™ Edition featuring hemp seed oil-based productsEndeavour Silver Reports Initial Drill Results for the El Curso Property Adjacent to the Guanacevi Mine in Durango, Mexico, Including 1,182 gpt Silver and 3.07 gpt Gold over 5